Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial.
Benjamin Z GalperKhaja M ChinnakondepalliKaijun WangElizabeth A MagnusonMichael LuVinod H ThouraniSusheel KodaliRaj MakkarHoward C HerrmannSamir R KapadiaMathew WilliamsJohn WebbCraig R SmithMichael J MackMartin B LeonDavid Joel Cohennull nullPublished in: Circulation (2023)
For patients with severe aortic stenosis and low surgical risk similar to those enrolled in the PARTNER 3 trial, transfemoral TAVR with the SAPIEN 3 valve is cost saving compared with SAVR at 2 years and is projected to be economically attractive in the long run as long as there are no substantial differences in late death between the 2 strategies. Long-term follow-up will be critical to ultimately determine the preferred treatment strategy for low-risk patients from both a clinical and economic perspective.
Keyphrases
- mitral valve
- aortic stenosis
- aortic valve replacement
- ejection fraction
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
- left ventricular
- aortic valve
- end stage renal disease
- study protocol
- early onset
- phase iii
- clinical trial
- heart failure
- coronary artery disease
- chronic kidney disease
- phase ii
- type diabetes
- hiv testing
- climate change
- replacement therapy